Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab Biomarker Study in RMS and PPMS
NCT02688985Phase 3Completed
- Sponsor
- Genentech
- Start
- Apr 2016
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of ocrelizumab in multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS) (5 arms), sponsored by Genentech. Primary endpoints: Neurofilament Light Chain Level in CSF at Week 240, CD19+ B Cell Count in CSF at Week 240 and 1 more. Started Apr 2016; status: completed.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on NCT02688985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02688985.